Prescribed at PEAK as part of a clinician-managed program
Common adverse reactions included nausea, diarrhea, and vomiting
Wegovy: A subcutaneous injection, Wegovy is approved along with a reduced-calorie diet and exercise for weight management in adults with obesity, adults with overweight and a weight-related disease, or children ages 12 years and over with obesity
Phase 3 TRIUMPH-4 Results: The Latest Data (December 2025) The first Phase 3 results for Retatrutide came from the TRIUMPH-4 trial, announced by Eli Lilly on December 11, 2025
These facilities are subject to current Good Manufacturing Practice (cGMP) requirements, undergo state-board oversight and quality documentation, and must perform and document batch-level testing for potency, sterility, endotoxin levels, and other quality parameters
It doesnt refer to a single specific product